Login to Your Account


Regeneron 'mountain' gene therapy effort in potential $640M eye deal with Avalanche

By Randy Osborne
Staff Writer

Tuesday, May 6, 2014
As investors await Regeneron Pharmaceuticals Inc.'s first quarter earnings, due Thursday, the company disclosed an ophthalmology deal with gene therapy specialist Avalanche Biotechnologies Inc. that buys a time-limited right to first negotiations to phase II-stage AVA-101, targeting vascular endothelial growth factor (VEGF) for wet age-related macular degeneration (AMD).

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription